ImmunoGen, Inc.
IMGNDelisted Feb 12, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000855654
ImmunoGen, Inc. was delisted on Feb 12, 2024; its insiders filed their last Form 4 on Feb 12, 2024; 327 institutions reported holding it in 13F filings for Q4 2023, worth $7.54B in total; Maverick Capital was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by ImmunoGen, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for ImmunoGen, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| McCluski Stephen C | Director | 0 | Feb 12, 2024 | 0 |
| Mitchell Dean J | Director | 0 | Feb 12, 2024 | 0 |
| Wallace Richard John | Director | 0 | Feb 12, 2024 | 0 |
| Peterson Kristine | Director | 0 | Feb 12, 2024 | 0 |
| Wingrove Theresa | SVP OF REGULATORY AFFAIRS | 0 | Feb 12, 2024 | 0 |
| Goldberg Mark Alan | Director | 0 | Feb 12, 2024 | 0 |
| Arbuckle Stuart A | Director | 0 | Feb 12, 2024 | 0 |
| Enyedy Mark J | CHIEF EXECUTIVE OFFICER | 0 | Feb 12, 2024 | 0 |
| Thackray Helen M. | Director | 0 | Feb 12, 2024 | 0 |
| McCain Tracey L | Director | – | Feb 12, 2024 | 0 |
| Vasconcelles Michael | EVP R&D & MEDICAL AFFAIRS | 0 | Feb 12, 2024 | 0 |
| Char Daniel | SVP & CHIEF LEGAL OFFICER | 0 | Feb 12, 2024 | 0 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS OFFICER | 0 | Feb 12, 2024 | 0 |
| Lentini Renee | VP & PRIN ACCTG OFFICER | 0 | Feb 12, 2024 | 0 |
| White Lauren | SVP, CFO AND PFO | – | Feb 12, 2024 | 0 |
| Kalofonos Isabel | SVP & CHIEF COMMERCIAL OFFICER | – | Feb 12, 2024 | 0 |
| Berkenblit Anna | SVP & CHIEF MEDICAL OFFICER | 113,935 | Jul 5, 2023 | 0 |
| ALTSCHULLER Susan | SVP AND CFO | – | Dec 27, 2022 | 0 |
| Harrington-Smith Kristen | SVP & CHIEF COMMERCIAL OFFICER | 25,000 | Nov 18, 2022 | 0 |
| Ryll Thomas | SVP, Technical Operations | 84,714 | Jul 2, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER | SSale | −4.58K | $29.30 | −$134.3K | −5.9%73.3K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −12.0K | $29.30 | −$352.4K | −36.4%21.0K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Enyedy Mark JCHIEF EXECUTIVE OFFICER | SSale | −20.1K | $29.28 | −$588.7K | −3.3%584.4K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Lentini ReneeVP & PRIN ACCTG OFFICER | SSale | −2.63K | $29.30 | −$77.1K | −15.2%14.7K after | 10b5-1 |
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −187.7K | $29.64 | −$5.56M | −98.2%3.43K after | 10b5-1 |
| Dec 27, 2023 (view filing) | Dec 26 | 1 day | Lentini ReneeVP & PRIN ACCTG OFFICER | SSale | −6.55K | $29.74 | −$194.7K | −43.7%8.45K after | 10b5-1 |
| Dec 19, 2023 (view filing) | Dec 15 | 4 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −117.4K | $29.40 | −$3.45M | −97.7%2.81K after | 10b5-1 |
| Dec 5, 2023 (view filing) | Nov 30 | 5 daysLate | Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER | SSale | −3.83K | $29.20 | −$111.7K | −10.4%33.1K after | 10b5-1 |
| Dec 5, 2023 (view filing) | Nov 30 | 5 daysLate | Peterson KristineDirector | SSale | −20.0K | $28.90 | −$578.0K | −100.0%0 after | 10b5-1 |
| Dec 1, 2023 (view filing) | Nov 29-30 | 2 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −171.2K | $28.46 | −$4.87M | −98.4%2.81K after | 2 lots10b5-1 |
| Nov 17, 2023 (view filing) | Nov 15 | 2 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −166.7K | $15.85 | −$2.64M | −98.3%2.81K after | 10b5-1 |
| Nov 17, 2023 (view filing) | Nov 15-17 | 2 days | Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER | SSale | −108.6K | $16.04 | −$1.74M | −74.6%37.0K after | 3 lots10b5-1 |
| Nov 8, 2023 (view filing) | Nov 7 | 1 day | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −19.5K | $16.66 | −$325.2K | −87.4%2.81K after | 10b5-1 |
| Nov 8, 2023 (view filing) | Nov 6 | 2 days | Lentini ReneeVP & PRIN ACCTG OFFICER | SSale | −219.5K | $15.29 | −$3.36M | −100.0%0 after | |
| Oct 18, 2023 (view filing) | Oct 16 | 2 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −192.0K | $14.40 | −$2.76M | −98.6%2.81K after | |
| Sep 19, 2023 (view filing) | Sep 15 | 4 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −192.0K | $15.44 | −$2.96M | −98.6%2.81K after | |
| Aug 11, 2023 (view filing) | Aug 9 | 2 days | Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER | SSale | −100.2K | $14.20 | −$1.42M | −90.1%11.0K after | |
| Aug 4, 2023 (view filing) | Aug 2-4 | 2 days | Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER | SSale | −84.6K | $17.10 | −$1.45M | −88.5%11.0K after | 2 lots |
| Aug 4, 2023 (view filing) | Aug 2-4 | 2 days | Enyedy Mark JCHIEF EXECUTIVE OFFICER | SSale | −3.01M | $17.01 | −$51.1M | −84.5%553.3K after | 4 lots |
| Aug 4, 2023 (view filing) | Aug 2 | 2 days | Lentini ReneePRIN. FIN & ACCTG. OFF. | SSale | −148.3K | $17.55 | −$2.60M | −86.7%22.8K after |